AtriCure, Inc. (NASDAQ:ATRC) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of AtriCure, Inc. (NASDAQ:ATRC) have received an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $52.00.

Several research firms recently commented on ATRC. UBS Group reduced their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Raymond James Financial set a $52.00 price target on AtriCure in a report on Tuesday, July 21st. BTIG Research increased their price objective on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, August 24th. Piper Sandler raised their price objective on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. Finally, Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th.

Insider Activity at AtriCure

In other news, insider Karl S. Dahlquist sold 9,370 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the sale, the insider owned 87,319 shares of the company’s stock, valued at approximately $4,269,025.91. This represents a 9.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Justin J. Noznesky sold 6,182 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the transaction, the insider owned 100,219 shares in the company, valued at approximately $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 61,379 shares of company stock worth $2,557,552 over the last quarter. Corporate insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

A number of hedge funds have recently made changes to their positions in ATRC. Amundi boosted its position in AtriCure by 17.2% during the second quarter. Amundi now owns 264,854 shares of the medical device company’s stock valued at $7,411,000 after purchasing an additional 38,922 shares in the last quarter. HighTower Advisors LLC bought a new stake in shares of AtriCure in the 2nd quarter valued at about $238,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in AtriCure during the second quarter valued at approximately $481,000. California State Teachers Retirement System lifted its position in AtriCure by 2,627.3% during the second quarter. California State Teachers Retirement System now owns 1,634,927 shares of the medical device company’s stock valued at $45,745,000 after acquiring an additional 1,574,980 shares during the last quarter. Finally, Three Seasons Wealth LLC acquired a new stake in AtriCure in the second quarter valued at approximately $200,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Price Performance

ATRC opened at $51.52 on Tuesday. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The business has a fifty day moving average of $40.10 and a 200 day moving average of $32.83. AtriCure has a 52-week low of $25.36 and a 52-week high of $53.50. The stock has a market cap of $2.62 billion, a P/E ratio of 245.35 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts anticipate that AtriCure will post 0.29 EPS for the current year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.